Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Stage III Multiple Myeloma
Isolated Plasmacytoma of Bone
Primary Systemic Amyloidosis
Extramedullary Plasmacytoma
Light Chain Deposition Disease
Stage I Multiple Myeloma
Stage II Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: cisplatin
Drug: doxorubicin
Drug: cyclophosphamide
Drug: etoposide
Drug: bortezomib
Drug: thalidomide
Drug: melphalan
Procedure: autologous stem cell transplant

First Posted Date: 2013-05-09

Last Posted Date: 2022-05-11

Lead Sponsor: Margarida Magalhaes-Silverman

Target Recruit Count: 41

Registration Number: NCT01849783

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Biological: Pegfilgrastim
Biological: 19-28z T CELLS
Procedure: Autologous Stem Cell Transplantation

First Posted Date: 2013-04-25

Last Posted Date: 2024-05-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01840566

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Brentuximab Vedotin
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2013-04-12

Last Posted Date: 2020-04-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 22

Registration Number: NCT01830777

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Stage III Non-Small Cell Lung Cancer AJCC v7
Stage IIIB Non-Small Cell Lung Cancer AJCC v7

Interventions: Radiation: Radiation Therapy
Drug: Carboplatin
Drug: Cisplatin
Drug: Erlotinib
Drug: Crizotinib
Drug: Etoposide
Drug: Paclitaxel

First Posted Date: 2013-04-02

Last Posted Date: 2019-08-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 59

Registration Number: NCT01822496

Locations: 🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸
Baptist Medical Center South, Jacksonville, Florida, United States

and more 170 locations

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 1

Completed

Conditions: Stage 2B Neuroblastoma
Stage 4S Neuroblastoma
Stage 1 Neuroblastoma
Stage 4 Neuroblastoma
Stage 2 Neuroblastoma
Ganglioneuroblastoma
Stage 2A Neuroblastoma
Stage 3 Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mesna
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Drug: Topotecan Hydrochloride
Drug: Vincristine Sulfate

First Posted Date: 2013-02-25

Last Posted Date: 2024-07-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 150

Registration Number: NCT01798004

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States

and more 120 locations

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Not Applicable

Withdrawn

Conditions: Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Ewing Sarcoma of Bone
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
Extraosseous Ewing Sarcoma
Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Interventions: Drug: etoposide
Drug: ifosfamide
Radiation: intensity-modulated radiation therapy
Drug: topotecan hydrochloride
Drug: busulfan
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: autologous bone marrow transplantation

First Posted Date: 2013-02-20

Last Posted Date: 2015-01-09

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT01795430

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Phase 2

Active, not recruiting

Conditions: Retinoblastoma

Interventions: Drug: vincristine
Drug: topotecan
Drug: filgrastim
Drug: PEG-filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Other: focal therapy
Drug: etoposide
Drug: MESNA
Drug: doxorubicin
Procedure: enucleation
Radiation: external beam radiation or proton beam radiation

First Posted Date: 2013-02-05

Last Posted Date: 2024-04-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 174

Registration Number: NCT01783535

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: AIDS-related Diffuse Mixed Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Lymphoblastic Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma
Stage IV AIDS-related Lymphoma
AIDS-related Diffuse Large Cell Lymphoma
Stage III AIDS-related Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma

Interventions: Drug: cyclophosphamide
Drug: lomustine
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: procarbazine hydrochloride
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2013-01-25

Last Posted Date: 2022-10-10

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 7

Registration Number: NCT01775475

Locations: 🇿🇼
University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
🇰🇪
Moi Teaching and Referral Hospital, Eldoret, Kenya

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: HIV-associated Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Splenic Marginal Zone Lymphoma
Stage IV AIDS-related Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: melphalan
Drug: etoposide
Drug: O6-benzylguanine
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis